I realize I may have sounded sarcastic in my brief response, but that was not my intent. Your logic is sound, but, for instance, the info arm does not match up with blended phase three at three years. So, the five year comparison assumption is only an assumption.
You see practicing physicians often have difficulty with these restrictions that are enforced upon drug and drug companies.They’re just not used to talking to their peers that way, and really they don’t have to except when talking on behalf of Northwest Biotherapeutics. The precarious position as the PI is that it is impossible for her not to speak of DC Vax without doing it on behalf of Northwest biotherapeutics. That balance and the tight rope is just not what they are used to at all. They are trained to project confidence in their decisions and opinions and not to worry about their mistakes. However it is clear to me that Linda Liau has been coached now multiple times by industry lawyers on what she can and cannot say. She is in a very special place because she is the overall PI and has a vested financial interest in the development and success of this product. She is very concerned of risk. You can tell this when you hear her speak about DC VAX Outside of a scientific conference. Her pacechanges she starts to correct her self and is not at all as confident in her wording.
If only management were as careful as her during this heightened period of risk.
Market Data 
Markets 
AI
